Island Pharmaceuticals Ltd · ASX:ILA
Island Pharmaceuticals — Investor Presentation (January 2026)
25 slides from Island Pharmaceuticals's investor presentation, Jan 27, 2026
Slide 1: Combatting Urgent Viral Disease Threats
For personal use only COMBATTING URGENT VIRAL DISEASE THREATS Dr David Foster, CEO & Managing Director January 2026 ASX: ILA
Slide 2: Two Programs Targeting Infectious Diseases
ISLAND PHARMACEUTICALS (ASX: ILA) TWO PROGRAMS TARGETING INFECTIOUS DISEASES For personal use only Phase 2a/b PROTECT clinical trial in dengue Two, well advanced clinical stage programs complete Positive FDA feedback on Animal Rule Major market potential via both programs regulatory path Multiple ne
Slide 3: Corporate Overview
CORPORATE OVERVIEW Share on issue¹: 269,052,397 Substantial shareholders Price per share¹: $0.43 Dr William James Garner³ 15.50% Market capitalisation¹: $115.7m Cash at bank (31 December 2025)²: $6.87m Jason Alan Carroll³ 11.92% For personal use only Potential additional capital from vested options
Slide 4: Company Overview
COMPANY OVERVIEW • Two clinical stage assets – Galidesivir and ISLA-101 - both with Priority Review Voucher potential based on approval For personal use only • Galidesivir: • Small molecule with broad antiviral activity against numerous high-priority threats • Robust development history with over US
Slide 5: An Urgent Threat: Lethal Filoviruses & Global Security
AN URGENT THREAT: LETHAL FILOVIRUSES & GLOBAL SECURITY For personal use only UNTAMED KILLERS HUMAN & ECONOMIC IMPACT • High Fatality Rates: Marburg up to 88%, Ebola up to 90% & Sudan up to 47% • Systemic organ failure • Limited defenses: No widely approved antivirals or • Hemorrhaging vaccines for M
Slide 6: Galidesivir Program Overview
GALIDESIVIR PROGRAM OVERVIEW • Small molecule with broad antiviral activity against numerous high-priority threats • Robust development history with over US$70m in funding to-date from US government • Confirmed regulatory pathway under the FDA’s Animal Rule • Qualifies for a Priority Review Voucher
Slide 7: FDA Response Significantly De-risks Regulatory Pathway
FDA RESPONSE SIGNIFICANTLY DE-RISKS REGULATORY PATHWAY Island has the potential to become to first Australian company to gain drug approval via the FDA’s Animal Rule For personal use only FDA confirmed the Clear guidance FDA advised that Island intends to Animal Rule provided on clinical Galidesivir
Slide 8: Potential Regulatory Path
POTENTIAL REGULATORY PATH 4~8 YEARS 4~6 YEARS 1 YEAR In vivo Basic Drug Experiment experiments Phase 1 Phase 2 Phase 3 NDA For personal use only study design in vitro (animal clinical trials clinical trials clinical trials studies) In vivo Basic Drug Experiment experiments Phase 1 Animal Rule NDA st
Slide 9: Galidesivir Provides Unprecedented Speed to Market
GALIDESIVIR PROVIDES UNPRECEDENTED SPEED TO MARKET The FDA has a number of paths for acceleration of pharmaceutical compounds to approval: - Fast Track Designation - Breakthrough Therapy Designation For personal use only - Accelerated Approval Pathway - Priority Review - Animal Rule Pathway (Special
Slide 10: High Efficacy in Marburg Non-Human Primate Study
HIGH EFFICACY IN MARBURG NON-HUMAN PRIMATE STUDY Treated non-human primates showed an overall survival rate of 94% during trial For personal use only Island Pharmaceuticals Limited 11
Slide 11: Marburg Non-Human Primate Study Summary
MARBURG NON-HUMAN PRIMATE STUDY SUMMARY For personal use only Study Group Virus Survivors (number) Total subjects Survival rate (%) Placebo Marburg 0 6 0% Galidesivir (1 hour) Marburg 5 6 83.33% Galidesivir (24 hour) Marburg 6 6 100% Galidesivir (48 hour) Marburg 6 6 100% Island Pharmaceuticals Limi
Slide 12: Animal Rule Is a Proven Path for Bioterror Threat Countermeasures
ANIMAL RULE IS A PROVEN PATH FOR BIOTERROR THREAT COUNTERMEASURES Since 2012, the FDA’s Animal Rule approval has For personal use only led to 8 bioterror countermeasures joining the US Strategic National Stockpile (SNS) In 7 out of 8 cases, these medical countermeasures continue to remain under SNS
Slide 13: Galidesivir Is Designed to Protect the Backbone of National Resilience
GALIDESIVIR IS DESIGNED TO PROTECT THE BACKBONE OF NATIONAL RESILIENCE For personal use only ILA’s stockpile strategy ensures full treatment coverage for the 10,000+ individuals critical to outbreak containment and continuity of government – from POTUS + Cabinet to Essential Infrastructure Leaders.
Slide 14: Broad Spectrum Activity Demonstrated
BROAD SPECTRUM ACTIVITY DEMONSTRATED Data highlights activity in vitro against multiple RNA viruses from diverse families Virus Family Virus Strain/Variant Virus Family Virus Strain/Variant For personal use only Marburg Musoke Nipah virus Malaysia Paramyxo HRS A2 Marburg Ci67 Filoviridae Measles Chi
Slide 15: Multiple Shots on Goal for Galidesivir
MULTIPLE SHOTS ON GOAL FOR GALIDESIVIR For personal use only Non-human Animal Rule Strategic National Virus Cell culture data Animal data PRV Eligible primate efficacy Potential Stockpile Potential Marburg Ebola Sudan Zika Chikungunya Island Pharmaceuticals Limited 15
Slide 16: PRV Prices Continue to Increase
PRV PRICES CONTINUE TO INCREASE FDA Priority Review Voucher (PRV) Sale Prices (2022-2026) For personal use only • Following expiration of two forms of PRVs the price has dramatically increased over the last 18 months. • With two programs that are currently PRV eligible, Island is in rare company wit
Slide 17: Near Term Milestones
NEAR TERM MILESTONES A number of value catalysts pending over the coming months for Galidesivir Galidesivir specific milestones Timeframe For personal use only Advance US Government engagement initiatives Complete Sign research agreement with gold-standard BSL4 facility and develop clinical trial pr
Slide 18: ISLA-101
For personal use only ISLA-101
Slide 19: Dengue - Common and Spreading
DENGUE - COMMON AND SPREADING Global cases of dengue fever rose steeply in 2024 HealthMap: Recent reports of local or imported Monthly global cases (millions) dengue cases (January 2026) For personal use only US$8.9B estimated impact to the economy from dengue fever Island Pharmaceuticals Limited 17
Slide 20: ISLA-101 – Broad Activity
ISLA-101 – BROAD ACTIVITY EVIDENT 1 DENGUE-4 1 • ISLA-101 has demonstrated broad anti-viral activity in in- For personal use only vitro models 2 ZIKA • Demonstrated potent anti dengue-1 activity in in-vitro models using fresh human cells • Protective in dengue fever and Zika in animal models 3 WEST
Slide 21: Preventing Animal Deaths from Lethal Dengue and Protective Against Zika
PREVENTING ANIMAL DEATHS FROM LETHAL DENGUE AND PROTECTIVE AGAINST ZIKA For personal use only Two daily doses of Isla101 prevent 70% of deaths by otherwise lethal dengue Survival curve showing protection from lethal dengue change by Increasing dose of ISLA101 (mouse model). Island Pharmaceuticals Li
Slide 22: Duration of Viral Load - RNAemia
DURATION OF VIRAL LOAD- RNAEMIA Duration of RNAemia For personal use only ISLA-101 treated subjects exhibited shorter exposure to virus \ • Control subjects had detectable viral RNA for ~10.5 days • Both treatment and preventative cohorts exhibited detectable viral RNA for ~8.5 days – two days short
Slide 23: Phase 2a/b (PROTECT) Design
PHASE 2A/B (PROTECT) DESIGN Phase 2A: Prophylactic (preventative) cohort High-level, unblinded results obtained • Phase 1 (completed April 2024) achieved all study outcomes For personal use only relating to safety and dosing, demonstrating benefit of Challenge study approach • Phase 2a (prophylactic
Slide 24: Evidence of Anti-Dengue Activity
EVIDENCE OF ANTI-DENGUE ACTIVITY • Using two measures of viral load, a clear reduction in viral load was witnessed in the preventative arm and trend towards viral load reduction in the treatment arm • Mean peak virus level (RNA) detected a reduction of 10-15x. For personal use only Peak Area Under t
Slide 25: Island Pharmaceuticals
For personal use only Island Pharmaceuticals ASX: ILA dfoster@islandpharmaceuticals.com islandpharmaceuticals.com @IslandPharma Island Pharmaceuticals
Island Pharmaceuticals — Investor Presentation (January 2026) on 6ix